Press Release
-
- (2025-09-19) AimedBio Receives Approval for KOSDAQ Listing
- 2025.10.14
-
- (2025-08-29) 3rd SMC X AimedBio ADC Conference Attracts 538 Industry and Academia Experts
- 2025.10.14
-
- (2025-08-25) AimedBio Named to Forbes Asia 100 to Watch 2025
- 2025.10.14
-
- (2025-06-24) Aimed Bio Clears Technical Hurdle for KOSDAQ Listing as ADC Pipeline Gains Momentum
- 2025.10.14
-
- (2025-06-19) AMB304, selected as a KDDF project
- 2025.10.14
-
- (2025-06-09) AMB303, Research Collaboration and License Option Agreement signed with SK Plasma
- 2025.10.14
-
- (2025-06-02) AimedBio secures 38 million USD in a pre-IPO funding round
- 2025.10.14
-
- (2025-04-17) AimedBio Receives IND Approval for AMB302 from Korea’s Ministry of Food and Drug Safety (MFDS)
- 2025.10.14
-
- (2025-02-14) AMB302 Granted Orphan Drug Designation (ODD) by the U.S. FDA
- 2025.10.14
-
- (2025-01-14) AimedBio Signs Exclusive Global Licensing Agreement with Biohaven for FGFR3 ADC, AMB302
- 2025.10.14
